The trial was prematurely halted after only 40% of subjects were enrolled because of concerns given recent guideline recommendations to preferentially use SGLT2 inhibitors, instead of DPP4 inhibitors, in patients with T2DM and HF, thus, significantly reducing the overall power of the study. The gene discussed is SLC5A2; the disease is hydrops fetalis.